LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
收藏DataCite Commons2025-09-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003603/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
提供机构：
Vivli
创建时间：
2019-04-12
